Call for Speaker Proposals
第1届
De-Risking Drug Discovery
-减轻创药风险学会-
各种标的和因应分子的策略与技术
2月21日～23日
这次是第一次举行的该学会，大学、关联业界、政府机关的代表者齐聚一堂，针对减轻临床前阶段及临床阶段医药品候选化合物风险的最新策略、手法和技术交换意见。由于减轻风险策略的进步，虽不能说是已充分具备，亦有可能评估风险、改善资源（人、资金、时间）的配置，或降低医药品整体的亏损率。此学会中，处理低分子及高分子化合物的制药和生物科技领域的专家齐聚一堂，分析为减轻风险可利用的手续、技术及商务面的方法等。此外，还有采用风险少的领导型化合物和将减轻制程风险的方法引进组织内、各种商务模式的方法及使其有效的方法、CRO中活用专业知识的方法、变更扩大开发失败的医药品和风险高的专案可能性之产品赋予的地位、以及变更目的等主题，亦针对标的重要性和减轻分子等级的风险、复数不同策略有必要的理由等进行讨论。若使用新技术或应用技术，就能改善创药风险或早期算出损失额。请勿错过能聆听创药、药物安全性、毒物学、展开医疗等领域的专家提示独自的方法论和经验，在各种活动中互相发表经验和专业知识，以及能与业界和学界专家建构人际关系的此机会。
Who should attend: CRO management, drug discovery leaders, translational scientists, executives, executive scientists, researchers, biomarker experts, and anyone interested in learning novel methods for de-risking.
Topics will include, but are not limited to:
- De-risking targets
- De-risking molecules
- Case studies: small molecules
- Case studies: large molecules
- New technologies & novel use of current technologies to expedite/facilitate
- Safety technologies
- Screening technologies
- in vivo models
- Novel platforms
- Drug repositioning
- Drug repurposing
- Business models
- Safety evaluations
- Role of translational medicine
- Contract research organizations
- Global strategy discussions
- Implementation of network pharmacology & translational science
The deadline for submission is July 29, 2011.
All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
